Rezolute(RZLT) - 2025 Q4 - Annual Results

Exhibit 99.1 · In August 2025, the Company achieved alignment with FDA on a significantly streamlined clinical development path for its ongoing Phase 3 study (upLIFT) of ersodetug for the treatment tumor HI. o The truncated study will include as few as 16 participants and will be limited to the single-arm open-label portion of the upLIFT study, removing the need to conduct a double-blind randomized placebo-controlled trial. o Enrollment is underway and topline results are expected in the second half of 2026 ...